Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer.

@article{Kovatcheva2004RecombinantHT,
  title={Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer.},
  author={Roussanka Kovatcheva and Tatjana D Hadjieva and Georgi G. Kirilov and Bojan S Lozanov},
  journal={Nuclear medicine review. Central & Eastern Europe},
  year={2004},
  volume={7 1},
  pages={13-9}
}
BACKGROUND Recombinant human TSH (rhTSH) has been developed to facilitate the follow-up for persistent or recurrent differentiated thyroid cancer (DTC), avoiding the hypothyroid symptoms after the withdrawal of Levothyroxine (L-T4) suppressive therapy. MATERIAL AND METHODS To analyse the effect of rhTSH in providing stimulation of radioiodine uptake (RAIU) for the ablation of thyroid remnant and/or malignant thyroid tissue in patients with metastatic DTC. Ten subjects (4 women, 6 men), mean… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-6 of 6 extracted citations

Similar Papers

Loading similar papers…